Ultrasound-guided ablation for hepatocellular carcinoma: Time for a reappraisal?

Expert Review of Anticancer Therapy

Volumn 15, Issue 2, 2015, Pages 147-150

  Cabibbo, Giuseppe ^a   Antonucci, Michela ^a   Sacco, Rodolfo ^b   Sciarrino, Elio ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c NONE   (Italy)

Author keywords

HCC; PEI; RFA

Indexed keywords

ALCOHOL;

ABLATION THERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED THERAPY; CRYOABLATION; ECHOGRAPHY; ELECTROPORATION; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PROBABILITY; RADIOFREQUENCY ABLATION; RECURRENCE FREE SURVIVAL; REVIEW; SURVIVAL TIME; SYSTEMATIC REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; ENDOSCOPIC ECHOGRAPHY; LIVER NEOPLASMS; PATHOLOGY; PROCEDURES;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; ETHANOL; HUMANS; LIVER NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84921500229     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2015.1001374     Document Type: Review

References (23)

1. Cabibbo G, Maida M, Genco C, et al. Causes of and prevention strategies for hepatocellular carcinoma. Semin Oncol 2012;39:374-83
2. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int 2009;29:478-80
3. Maida M, Orlando E, Camma C, Cabibbo G. Staging systems of hepatocellular carcinoma: a review of literature. World J Gastroenterol 2014;20: 4141-50
4. Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73
5. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-30
6. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43
7. Sacco R, Gadaleta-Caldarola G, Galati G, et al. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers? Future Oncol 2014;10(10):1719-21
8. Maida M, Cabibbo G, Brancatelli G, et al. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol 2013;9:845-54
9. Cabibbo G, Maida M, Genco C, et al. Survival of patients with hepatocellular carcinoma (HCC) treated by percutaneous radio-frequency ablation (RFA) is affected by complete radiological response. PLoS One 2013;8:e70016
10. Orlando A, Leandro G, Olivo M, et al. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009;104:514-24
11. Cho YK, Kim JK, Kim MY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009;49:453-9
12. Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol 2010;52:380-8
13. Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res 2011;31: 2291-5
14. Oeda S, Mizuta T, Isoda H, et al. Survival advantage of radiofrequency ablation for hepatocellular carcinoma: comparison with ethanol injection. Hepatogastroenterology 2013;60:1399-404
15. Shen A, Zhang H, Tang C, et al. Systematic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol 2013;28:793-800
16. Forner A, Bruix J. Ablation for hepatocellular carcinoma: is there need to have a winning technique? J Hepatol 2010;52:310-12
17. Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013;59:300-7
18. Pompili M, Mirante VG, Rondinara G, et al. Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation: assessment of efficacy at explant analysis and of safety for tumor recurrence. Liver Transpl 2005;11:1117-26
19. Branco F, Bru C, Vilana R, et al. Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma. Ann Hepatol 2009;8:220-7
20. Eguchi S, Hidaka M, Tomonaga T, et al. Actual therapeutic efficacy of pre-transplant treatment on hepatocellular carcinoma and its impact on survival after salvage living donor liver transplantation. J Gastroenterol 2009;44:624-9
21. Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-32
22. Genco C, Cabibbo G, Maida M, et al. Treatment of hepatocellular carcinoma: present and future. Expert Rev Anticancer Ther 2013;13(4):469-79
23. Bruix J, Tatayama T, Mazzaferro V, et al. STORM: a phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2004; 32(5s Suppl)):abstract 4006